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Introduction
A fraction of the cancer cells that disseminate from primary tumors and migrate to distant sites will result in the formation of a lethal metastatic tumor (Hanahan and Weinberg, 2011) . Migrating tumor cells found in the peripheral bloodstream are called circulating tumor cells (CTCs), while theor counterparts found in bone marrow are called disseminated tumor cells (DTCs) (Alix-Panabieres and Pantel, 2016) .
CTCs have been regarded as a critical stage in the development of metastasis, in that they contain genetic and molecular information about the cancer as well as its evolutionary adaptation to prior therapies (Alix-Panabieres and Pantel, 2016) .
However, CTCs have also been detected in the blood circulation of healthy volunteers, and in patients with benign diseases of the lung, colon, pancreas, and breast (Alva et al., 2015; Cauley et al., 2015; Franken et al., 2012; Ilie et al., 2014; Liu et al., 2015; Markou et al., 2014; Pantel et al., 2012) .
CTCs have paved new diagnostic avenues in liquid biopsy diagnostics, especially for tumors that are not easy to biopsy and for metastatic lesions (Azarin et al., 2015) .
Early detection of cancer metastasis is always difficult, not to mention its prevention or cure. With its non-invasive nature and real-time advantage, cancer screening for CTCs can be applied to populations at higher risk. Therefore, oncologists place high hopes on CTC-based screening methods which have been found to be more sensitive than current imaging methods such as PET scan (Hegemann et al., 2016) . The consistency between CTCs and their primary tumors is encouraging, and may provide This article has not been copyedited and formatted. The final version may differ from this version.
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5 an excellent opportunity for clinicians to examine mutations of key genes that are not detected through traditional blood-based assays (Nagrath et al., 2016) . In the era of precision medicine in cancer therapy, systemic monitoring of response to anti-cancer therapies is a key step toward providing personalized care. An increasing body of evidence indicates that, in the course of the treatment, assessment of the molecular characteristics of the progressive disease is more significant than depending on the primary tumor samples, which do not reflect the evolution of the tumor (AlixPanabieres and . For their comprehensive information regarding the whole disease, studies of CTCs not only reveal the underlying mechanism of tumorigenesis and metastasis, but also provide a non-invasive method for cancer diagnosis, prognosis, and pharmacotherapy monitoring (Masuda et al., 2016) .
Recent research has demonstrated that CTCs, an integral part of the "liquid biopsy", have great potential to change the status quo of anticancer therapy; however the approach remains technically challenging. Following a short discussion of the significant roles of CTCs in cancer metastasis and currently available methods for the CTCs detection and molecular characterization，this review will focus on the clinical applications of CTCs as markers for prognosis prediction in cancer patients and as indicators in cancer pharmacotherapy (Figure 1 ).
CTCs and cancer metastasis
The malignant form of cancer and the cause for more than 90% of cancer-associated This article has not been copyedited and formatted. The final version may differ from this version. 
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6 mortality is metastasis, which os characterized by the ability of cancer cells to invade into the surrounding tissue and disseminate throughout the body to establish secondary tumors in distant organs (Gupta and Massague, 2006) . As shown in Figure 2 , the sequential metastasis processes first initiates with a loss of adhesion of tumor cells in the primary site and their migration out of the primary tumor. Secondly, the tumor cells attach to blood vessels and invade into the blood or lymphatic circulation in a process called intravasation (Fidler, 2003) . As the tumor cells circulate to the secondary site, the tumor cells intrude blood vessels to adhere to the target organ endothelium and migrate into the parenchyma; this is called extravasation (Chaffer and Weinberg, 2011; Klein, 2009; Sosa et al., 2014) . Therefore, the existence of CTCs has been recognized as an important "intermediate step" in cancer metastasis. CTCs represent a stem-like sub-population of cells that are capable of immigration and tumor initiation (Al-Hajj et al., 2003; Ricci-Vitiani et al., 2007; Stewart et al., 2011) . During the metastasis process, many cell surface markers of CTCs undergo change. The activation of epithelial to mesenchymal transition (EMT) facilitates tumor cell invasion and dissemination during intravasation, while its reverse process, a mesenchymal to epithelial transition (MET), is believed to support extravasation once cancer cells have arrived in distant organs (Acloque et al., 2009; Nieto, 2013; Thiery et al., 2009) . It has been speculated that the entire process in which CTCs seed metastasis occurs with extremely low efficiency; only 0.01% of all CTCs can survive and form micrometastases in distant organs (Luzzi et al., 1998 and eventually die from anoikis. Therefore, CTCs sometimes aggregate to form microemboli (circulating tumor microemboli, CTM), which may endow tumor cells advantages in survival and enhabces CTCs viability and motility (Krebs et al., 2014) .
For several decades, the lack of relevant models for metastasis research extensively limited further investigation. CTCs are the true link between primary and metastatic tumors, and thus create a new opportunity for investigators to explore valuable features of both primary and metastatic sites, as well as specific details of the processes of intravasation, migration, and extravasation.
CTC detection
As mentioned above, after release from the main and/or metastatic tumor site into the blood circulation, the conditions in the blood are harsh for epithelial tumor cells, and the survival time of CTCs is extremely short (half-life: 1-2.4 hours) (Meng et al., 2004) .
Apoptotic and fragmented CTCs are frequently detected in the peripheral bloodstream of cancer patients (Larson et al., 2004) . Therefore, a pivotal challenge for the clinical application of CTCs is the capability of the current CTC technology to efficiently capture the extremely rare CTC population from patient blood samples for subsequent processing (Nelson, 2010) .
In the past decade, one of the most widely used strategies to detect CTCs has been the use of epithelial markers such as cytokeratins (CK) and EpCAM, which are not detected and as well as for negative staining for CD45 (Riethdorf et al., 2007) .
However, further research has demonstrated that epithelial tumor cells are likely to undergo EMT, which results in decreased expression of epithelial markers and increased plasticity, migration, and invasiveness (Mani et al., 2008) . These partial EMT tumor cells, also called the "intermediate phenotype," have the highest versatility to adapt to the microenvironment in secondary sites (Tam and Weinberg, 2013) . Therefore, in recent years a variety of devices have been developed for the enrichment and detection of CTCs undergoing EMT, in addition to the approaches selecting for epithelial markers (Alix-Panabieres and Pantel, 2014) . CTC assays usually involves two steps: first, an enrichment step increases the percentage of CTCs, making it easier ti detect single tumor cells. Specifically, CTCs can be enriched by their biologic characteristics (e.g., protein markers) or on the basis of their physical properties (e.g., size, density, deformability, or electric charges). Second, in the detection step, CTCs can be selected using different criteria such as immunologic, molecular, or functional assays (Table 1) (Ferreira et al., 2016 
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9 developed rapidly, sensitivity and specificity are still problems that hinder the clinical utilization of CTCs for guiding personalized treatment of cancer patients (Hardingham et al., 2015) .
CTCs as prognostic markers in cancer
To date, CTCs enumeration has been widely used as a prognostic index for patient overall survival rate. A cut-off value of ≥5 or ≥3 CTCs in 7.5 ml blood has been proved to be a poor prognostic index in several cancers, including breast cancer (Zhang et al., 2012) (Schulze et al., 2013) , esophageal cancer (Vashist et al., 2012) , melanoma (Rao et al., 2011) , head and neck carcinoma (Nichols et al., 2012) , and pancreatic cancer (Han et al., 2014) .
The association between detection of CTCs and clinical outcome has been most widely studied in breast cancer. For example, CTCs were analyzed in a pool of 2026 patients with early stage breast cancer before pharmacotherapy and 1492 patients after pharmacotherapy using the CellSearch System (Rack et al., 2014) . In the prepharmacotherapy group, CTCs were found in 21.5% of patients, in which 19.6% were lymph node-negative and 22.4% were node-positive. 
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10 rates for disease-free survival (DFS), distant DFS, breast cancer-specific survival, and overall survival. CTCs were identified as an independent prognostic index for DFS in multivariable analysis. Patients with more than five CTCs per 30 mL blood had the worst prognosis. These results from a large-scale trial of patients with breast cancer suggested that CTCs have prognostic value (Rack et al., 2014) .
Of note, in these reports indicating that CTCs can be used as a reliable early index of disease progression and survival as compared to traditional methods, a significant proportion of patients with obvious distant metastases were negative for CTCs. This result implied that CTCs undergoing EMT transformation can be missed by epithelial marker based detection methods, such as the CellSearch system. Therefore, large-scale multicenter trials with improved CTC detection techniques and well-defined endpoints are needed to support the clinical utility of CTC detection in cancer patients.
CTC as indicators in pharmacotherapy
CTCs may be disseminated from the primary tumor or from a number of metastatic sites. Therefore, CTCs offer a wealth of genetic and molecular information cincerning the cancer at the protein, RNA, and genome levels (Meng et al., 2004) . Bin addition to CTC detection, significant effort has been made towards CTC characterization. In the era of precision medicine of cancer therapy, identification of CTCs expressing certain markers can be used to specifically monitor cancer therapy. 
5.1.CTCs as markers for targeted therapy selection
Molecular alterations in CTCs have proved to be highly consisted with the primary tumor, which provides robust evidence for the clinical application of targeted therapy in cancer. Several studies have suggested CTCs as an index of therapy selection and, furthermore, as a real-time biopsy to reflect the effect of a particular therapy.
For example, BRAF mutation between primary tumors and metastases have been described within a patient; these mutations mediate tumor proliferation through activation of the RAF-MEK-ERK pathway (Lin et al., 2011) . Therefore, the BRAF mutation status in CTCs collected from patients with metastatic melanoma is a pivotal index for selecting targeted therapies such as Vemurafenib and Dabrafenib (Jang and Atkins, 2014; Reid et al., 2015) . Another case in point are EGFR mutations in lung cancer. A group of pulmonary adenocarcinoma that have activating EGFR mutations are exclusively sensitive to EGFR tyrosine kinase inhibitors (Mok et al., 2009 ).
Therefore, EGFR mutations in CTCs are clinical biomarkers for categorization of pharmacotherapies target in metastatic lung cancer with respect to treatment with Erlotinib, Afatinib, and Osimertinib (Breitenbuecher et al., 2014; Kuwano et al., 2016) .
In addition to melanoma and lung cancer, therapeutic targets were identified in breast cancer. The PI3K/AKT/mTOR pathway is frequently altered in cancer. PI3K is a cell membrane signal transduction molecule that supports cell survival and growth, making it a popular therapeutic target (Akinleye et al., 2013; Wong et al., 2010) . PIK3CA mutations were identified in CTCs from metastasis breast cancer patients by CellSearch 
CTCs as markers of treatment resistance
It has been reported that, in both early and metastatic cancers, the presence of CTCs following treatment can act as a predictive index of the possibility of disease recurrence et al., 2015) . AR-V7 expressed in CTCs may therefore serve as a biomarker for CRPC treatment selection (Onstenk et al., 2015) . These results add to existing evidence that CTCs are a valuable tool to optimize personalized cancer treatments and improve the prognosis for therapy-resistant patients.
5.3.CTC as a biomarker for treatment sensitivity
Increasing evidence points out the significance of evaluating molecular features of the advancing disease during therapy, instead of depending on the primary tumor sample increasea in CTC number (≥5 CTCs/7.5 mL) after one cycle treatment were regarded as at higher risk group for early cancer progression. These patients were randomly designated into a continued first-line pharmacotherapy group or another treatment group before radiologic evaluation of progression (Bidard et al., 2016) . For patients with continued increases in CTC numbers after first-line chemotherapy, a more effective treatment than standard chemotherapy is needed (Smerage et al., 2014) . mL blood received endocrine therapy as the first-line treatment (Lianidou and Markou, 2011) . In a phase II trial of Erlotinib and Pertuzumab in advanced non-small cell lung cancer, CTC counts were associated with treatment response rates, which were correlated with fludeoxyglucose-positron emission tomography (Punnoose et al., 2012) .
Future prospect and challenges
There is no doubt that innovative approached utilizing CTCs have paved new diagnostic avenues for the next generation of liquid biopsy diagnostics, especially in tumors that are not easy to biopsy and in metastatic lesions. Furthermore, based on their noninvasive and real-time advantages, CTCs can be applied for cancer screening of populations at higher risk. Identification and characterization of CTCs have been applied in several key clinical areas, such as prognosis prediction, systemic pharmacotherapy selection, and monitoring. However, although some promising results have been reported, detection of CTCs still faces serious challenges including sensitivity and specificity. In the future, more efficient capture systems and larger panels of detection markers will be explored to avoid losing assay specificity while increasing sensitivity. In conclusion, the detection and characterization of CTCs will provide new biological perspectives and clinical implications for cancer patients, especially during pharmacotherapy.
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